human | Q5 |
P496 | ORCID iD | 0000-0002-0664-0709 |
P69 | educated at | Aarhus Faculty of Health Sciences | Q4661705 |
P108 | employer | Rigshospitalet | Q3357360 |
P734 | family name | Witting | Q21488913 |
Witting | Q21488913 | ||
Witting | Q21488913 | ||
P735 | given name | Nanna | Q16422888 |
Nanna | Q16422888 | ||
P106 | occupation | researcher | Q1650915 |
P21 | sex or gender | female | Q6581072 |
Q53559144 | A PET activation study of brush-evoked allodynia in patients with nerve injury pain. |
Q48695686 | A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy |
Q35890267 | Aerobic Training in Patients with Congenital Myopathy |
Q31032086 | Axial myopathy: an overlooked feature of muscle diseases. |
Q60772362 | Becker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2 |
Q114905389 | Botulinum toxin treatment improves dysphagia in patients with oculopharyngeal muscular dystrophy and sporadic inclusion body myositis |
Q35582438 | Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E |
Q53634475 | Clinical and neurophysiological response to pharmacological treatment of DOK7 congenital myasthenia in an older patient. |
Q48226149 | Collagen XII myopathy with rectus femoris atrophy and collagen XII retention in fibroblasts |
Q52565198 | Congenital titinopathy: Comprehensive characterisation and pathogenic insights. |
Q28542539 | Decreased variability of the 6-minute walk test by heart rate correction in patients with neuromuscular disease |
Q41855877 | Deletion of exon 26 of the dystrophin gene is associated with a mild Becker muscular dystrophy phenotype. |
Q60772388 | Differential recruitment of endogenous pain inhibitory systems in neuropathic pain patients |
Q60772304 | Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy |
Q48590768 | Effects of Sildenafil on Cerebrovascular Reactivity in Patients with Becker Muscular Dystrophy. |
Q60772295 | Endocrine function over time in patients with myotonic dystrophy type 1 |
Q37610554 | Frequency and Phenotype of Myotubular Myopathy Amongst Danish Patients with Congenital Myopathy Older than 5 Years |
Q51162545 | Frequency and phenotype of patients carrying TPM2 and TPM3 gene mutations in a cohort of 94 patients with congenital myopathy. |
Q34421461 | Has basic research contributed to chronic pain treatment? |
Q51743589 | High prevalence of cardiac involvement in patients with myotonic dystrophy type 1: a cross-sectional study. |
Q36615476 | Loss-of-function mutations in SCN4A cause severe foetal hypokinesia or 'classical' congenital myopathy. |
Q30413900 | Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. |
Q35576188 | Myocardial fibrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance study |
Q60772312 | Ocular, bulbar, limb, and cardiopulmonary involvement in oculopharyngeal muscular dystrophy |
Q38178549 | Pharmacologic treatment of downstream of tyrosine kinase 7 congenital myasthenic syndrome. |
Q54116685 | Phenotype and genotype of muscle ryanodine receptor rhabdomyolysis-myalgia syndrome. |
Q37716090 | Phenotypes, genotypes, and prevalence of congenital myopathies older than 5 years in Denmark |
Q41588609 | Prevalence and phenotypes of congenital myopathy due to α-actin 1 gene mutations. |
Q60772288 | Progression of cardiac involvement in patients with limb-girdle type 2 and Becker muscular dystrophies: A 9-year follow-up study |
Q60772242 | Reliability of the 2- and 6-minute walk tests in neuromuscular diseases |
Q60772400 | Repetitive intradermal capsaicin: differential effect on pain and areas of allodynia and punctate hyperalgesia |
Q60772354 | Response |
Q54397896 | Severe axial myopathy in McArdle disease. |
Q48011157 | The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. |
Q53220865 | Two- and 6-minute walk tests assess walking capability equally in neuromuscular diseases. |
Search more.